These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Chew DP; Bhatt DL; Sapp S; Topol EJ Circulation; 2001 Jan; 103(2):201-6. PubMed ID: 11208677 [TBL] [Abstract][Full Text] [Related]
5. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes. Harrington RA Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670 [TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Leclerc JR Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256 [TBL] [Abstract][Full Text] [Related]
7. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127 [TBL] [Abstract][Full Text] [Related]
8. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Berkowitz SD Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626 [TBL] [Abstract][Full Text] [Related]
9. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Roffi M; Mukherjee D; Chew DP; Bhatt DL; Cho L; Robbins MA; Ziada KM; Brennan DM; Ellis SG; Topol EJ Circulation; 2002 Dec; 106(24):3063-7. PubMed ID: 12473552 [TBL] [Abstract][Full Text] [Related]
10. Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments. Curtin R Curr Pharm Des; 2004; 10(14):1577-85. PubMed ID: 15134556 [TBL] [Abstract][Full Text] [Related]
11. Oral GPIIb/IIIa antagonists: what went wrong? Cox D Curr Pharm Des; 2004; 10(14):1587-96. PubMed ID: 15134557 [TBL] [Abstract][Full Text] [Related]
12. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. Murphy J; Wright RS; Gussak I; Williams B; Daly RN; Cain VA; Pieniaszek HJ; Sy SK; Ebling W; Simonson K; Wilcox RA; Kopecky SL Am J Cardiovasc Drugs; 2003; 3(2):101-12. PubMed ID: 14727937 [TBL] [Abstract][Full Text] [Related]
13. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Quinn MJ; Plow EF; Topol EJ Circulation; 2002 Jul; 106(3):379-85. PubMed ID: 12119257 [No Abstract] [Full Text] [Related]
20. Is there a role for oral blockade of platelet glycoprotein IIb/IIIa receptors in coronary and cerebrovascular disease? Salam AM Expert Opin Investig Drugs; 2003 Oct; 12(10):1709-12. PubMed ID: 14519089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]